High-affinity MRGPRX2 inhibitors are expected to be applied to areas where there are few effective therapeutic agents, such as postoperative pain, migraine, and drug-induced acute pseudoallergic reactions. The gene discussed is MRGPRX2; the disease is migraine disorder.